A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Inclusion Criteria: * Confirmed clinical diagnosis of ulcerative colitis (UC) at least 3 months before screening * Moderately to severely active UC as defined by Mayo score * History of inadequate response to or failure to tolerate conventional therapy * Has screening laboratory test results within the study protocol defined parameters * A woman of childbearing potential must have a negative highly sensitive serum (beta human chorionic gonadotropin) pregnancy test result at screening and a negative urine pregnancy test result at Week 0 Exclusion Criteria: * Has severe extensive colitis as defined in the study protocol * Has UC limited to the rectum only or to less than (\<) 20 centimeter (cm) of the colon * Has a history of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, before screening * Has any known malignancy or has a history of malignancy (with the exception of basal cell carcinoma; squamous cell carcinoma in situ of the skin; or cervical carcinoma in situ that has been treated with no evidence of recurrence; or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years before screening) * Has known allergies, hypersensitivity, or intolerance to guselkumab or golimumab or their excipients